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Predominant Thi cell infiltration in acute rejection episodes of human
kidney grafts. T-cells and their cytokines are thought to play a major role
in the genesis of cellular infiltration and rejection in human kidney
allografts. Production of Thi (IFN-y) and Th2-type (IL-4 and IL-5)
cytokines was assessed in a large series of T-cell clones, derived from core
biopsies of kidney grafts in 10 patients with acute interstitial grade I/TI
rejection (AIR), 6 patients with a histology of "borderline rejection"
(BLR) and 3 with cyclosporine A (CsA) toxicity, all receiving standard
maintenance immunosuppression. Biopsies were pre-cultured in IL-2 in
order to preferentially expand T-cells activated in vivo, and T-cell blasts
were cloned with phytohemagglutinin (PHA) and TL-2 using a highly
efficient (23 to 98%) cloning technique. A total of 483 T-cell clones
obtained from AIR episodes were compared with 346 and 132 clones
derived from patients with BLR episodes and UsA toxicity, respectively. In
two series of 22 AIR and 77 BLR T-cell clones, alloreactivity against
donor cells was shown by 25 and 14% of CD8 and 21 and 4% of CD4
clones, respectively. When stimulated by donor-derived EBV B-cells, all
these alloreactive clones produced IFN-y, but not IL-4 or IL-5 (Thi
clones). Upon stimulation with PHA, the principal qualitative and quan-
titative differences between AIR- and BLR-derived T-cell clones were that
cells derived from AIR patients: (i) showed significantly higher propor-
tions (80 15 vs. 55 13%) of Thi clones in their progeny; (ii) included
smaller proportions (3 4 vs. 20 17%) of clones incapable of producing
IFN-y, IL-4 or IL-5 ('null' clones); and (iii) produced significantly higher
quantities of IFN-y (100 50 vs. 36 7 U/b6 cells/mi), these quantities
also being significantly correlated (r = 0.83) with the degree of interstitial
graft infiltration (item i in the Banif histological grading). The clones
derived from UsA toxicity biopsies exhibited a pattern very similar to that
found in BLR cases. These data lead us to conclude that the powerful
inflammatory response elicited in acute rejection of a kidney graft recruits
and activates both allospecific and non-specific Thi effector cells, which
are primed to high IFN-y production. Our results also suggest that IFN-y
could contribute, at least in part, to the degree of graft infiltration and to
the severity of the rejection episode.
Allograft rejection results from the coordinated activation of
the recipient's alloreactive T-cells, which recognize donor alloan-
tigens either directly as unmodified molecules on the surface of
donor antigen-presenting cells (APC) or indirectly as processed
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allogeneic peptides presented by recipient APCs [1]. Alloreactive
T-cells include both MHC class IT-restricted CD4 T-cells and
MHC class I-restricted CD8 T-cells. It has been suggested that
some Thi-dependent effector mechanisms, mainly related to
delayed-type hypersensitivity and cytotoxic T lymphocyte (CTL)
activity, play a central role in acute allograft rejection [2, 3]. In
human kidney allografts, infiltration by mononuclear cells is the
histological hallmark of episodes of acute interstitial rejection
(AIR), and the extent to which cultured T lymphocytes from
biopsy growth in vitro have been correlated with rejection [4, 5]. It
has also been shown that rejected kidney grafts harbor T-
lymphocytes whose clonal progeny include alloreactive T-cells
expressing cytotoxicity against donor-derived EBV-transformed
B-cell lines [6] or parenchymatous kidney cells [5] even after
several weeks of culture.
Cytokines are probably involved in the genesis of the lesions
characteristic of allograft rejection. It has been reported that
during acute rejection episodes serum levels of TNF-a, IL-i and
IL-6 are increased, and that within the graft these cytokines are
overexpressed [7—9]. Consonant results have not yet been ob-
tained, however, in studies of the transcription of cytokine mRNA
carried out using in situ hybridization or RT-PCR with mRNA
extracted from core biopsies or fine needle aspirates. Of the
Thi-type cytokines, mRNA for IFN-y is consistently expressed in
human renal allografts prior to or during rejection [10—12]. IL-2
mRNA is found in similar circumstances, if somewhat less con-
sistently [13—15], but mRNA for IL-12 (a key cytokine in the
polarization of Thi responses [16, 17]) is nevertheless not associ-
ated with rejection [181. On the other hand, mRNA for IL-4 were
very rarely detected in renal allografts undergoing rejection [14,
15, 19]. These discrepancies may be related to differences in
methodology, in drug therapy, and in clinical definitions of
rejection.
Accumulation of IL-2 and IFN-y mRNA during rejection has
been observed most consistently in experimental transplantation,
where no immunosuppression is given [3, 20]. Conversely, in vivo
studies of cytokine expression patterns during the induction of
tolerance have consistently shown a dramatic decrease in the
expression of IL-2 and IFN-y, and in some models an increase in
IL-4 and IL-b transcripts, for example, when anti-CD4 was used
[21—24]. Although it remains to be proven, the ThliTh2 paradigm
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may thus represent a basis for understanding at least some of the
mechanisms of rejection and tolerance in transplantation [2, 25].
Other findings, however, do not fit an explanation along such
lines. For instance, very low levels of transcripts for both Thi-
(IL-2, IFN-y) and Th2- (IL-4, iL-b and IL-13) related cytokines,
or even decreased IL-4 levels, have been found within heart or
liver allografts in tolerant animals [20, 26, 27].
In humans, the ThI/Th2 cell balance in rejected or "tolerated"
(that is, accepted) grafts has not yet been explored at the clonal
level. Indeed, in patients on immunosuppressive treatment, well
accepted grafts have low levels of infiltration and do not require
histological inspection, making any possible imbalance in cytokine
production difficult to assess. Nor has any attempt yet been made
to correlate cytokine production in the graft with the degree of
rejection, even in patients with a histological pattern of "border-
line" rejection in whom the decision to treat has not been firmly
established.
ThO, Thi and Th2 clones have been defined in rodents, and the
concept has been also more recently validated in humans [28].
The aim of this study was to assess the production of Thi and Th2
type cytokines (IFN-y, IL-4 and IL-5) in a large series of T-cell
clones derived from the core biopsy of kidney allografts in patients
undergoing interstitial rejection with a histology of either clear
acute grade I/lI rejection (AIR) or a pattern of "borderline"
rejection (BLR), or in three additional cases, no rejection (CsA
toxicity). The principal qualitative and quantitative differences
between BLR and AIR revealed in this study were that patients
with AIR showed: (i) significantly higher proportions of Thi
effectors in the clonal progeny of graft-infiltrating T-cells, and (ii)
significantly higher IFN-y production at clonal level, which ap-
pears to be closely correlated with the degree of interstitial graft
infiltration as assessed by Banif histological grading.
Methods
Patients and kidney graft biopsies
Nineteen biopsies in 19 kidney allograft recipients were studied.
Table 1 shows the principal clinical parameters of the recipients as
well as the Banif grading of each biopsy from grade I/Il acute
interstitial rejection (AIR) and borderline rejection (BLR) epi-
sodes.
Ten samples were classified as showing an episode of grade I
(N = 7) or grade II (N = 3) acute interstitial rejection (AIR). The
mean number SD of HLA mismatches in this group of patients
was 4.8 1, with one full mismatch (patient #1). Mean serum
creatinine level at the time of biopsy was 331.2 162.8 sM with
a percentage increment from the pre-rejection nadir of 87.5
52.2%. All rejection episodes were treated with boluses of corti-
costeroids. Three patients had rescue treatment (anti-CD3 mAb
in patient #11, anti-thymocyte globulin in patient #24) and one
(patient #8) presented with an episode of rejection relapse on day
47. Seven patients' serum creatinine returned to pre-rejection
nadir levels within three months of the acute rejection episode,
whereas three were subject to long lasting renal dysfunction.
Six biopsies showed histology described as "borderline" (BLR)
in terms of the Banif classification [29]. The characteristics of
these patients are also set out in Table 11. The number of HLA
mismatches in this group (3.5 1.7) did not differ significantly
from that observed in the AIR group. As is often the case with
"borderline" histology, treatment and outcome were less homo-
geneous than in AIR. In the three patients without delayed graft
function (DGF), the mean creatinine level at the time of biopsy
was 294.3 82.9 /SM. Two patients with DGF were still under
dialysis when biopsied, and another patient was biopsied for a
persistently altered graft function with a plateau in serum creat-
mine level at about 300 M. In two patients, the decision not to
treat was maintained and was followed by a spontaneously
favorable outcome. Three patients were treated (with corticoste-
roid boluses), leading to a good outcome in two, while in the third
(patient #3), treatment brought about no further change in his
persistently altered graft function. Finally, only one patient pre-
sented with CMV disease three weeks before biopsy (case number
2) and was treated with ganciclovir.
Three cases of typical CsA toxicity (patients #20, #26 and
#30), with one associated with a weak ATN (patient #26) were
included as additional controls. One last patient had a biopsy
considered almost normal (systematic biopsy at 4 years, per-
formed as part of a specific protocol to assess the long-term effect
of a double therapy regimen) with the following Banif grading: gO,
iO, tO, ahi, iO.
Reagents
Recombinant human IL-2 was kindly provided by Eurocetus
(Milan, Italy). Recombinant human IL-5 was purchased from
Amgen Biologicals (Thousand Oaks, CA, USA). PHA was pur-
chased from Gibco Laboratories (Grand Island, NY, USA) and
phorbol 12-myristate 13-acetate (PMA) from Sigma (St. Louis,
MO, USA). Staphylococcal enterotoxins SEA, SEB, SED and
SEE were purchased from Serva (Heildelberg, Germany). Anti-
CD3, anti-CD4 and anti-CD8 mAbs were purchased from Ortho
Pharmaceuticals (Raritan, NJ, USA).
Generation of T-cell clones
Each kidney graft biopsy was cultured for a maximum of nine
days in 10 ml RPMI 1640 medium supplemented with 2 mM
L-glutamine, 2 X 10 M 2-ME 10%, heat-inactivated fetal calf
serum (complete medium), and human recombinant IL-2 (50
U/mi) in order to expand preferentially T-cells activated in vivo.
Biopsy specimens were then disrupted and T-cell blasts were
cloned under limiting dilution conditions (0.3 cells/well) in round-
bottomed microwell plates containing iO irradiated allogeneic
PBMC (as feeder cells), PHA (0.5% vol/vol) and IL-2 (20 U/mi),
as reported elsewhere in detail [30]. Surface marker analysis of
T-cell clones was performed on a Cytoron Absolute cytofluorom-
eter (Ortho Pharmaceuticals).
Screening assay for graft-infiltrating T-cell clone responsiveness to
staphylococcal enterotoxins
T-cell blasts (5 X i0) from all CD4 and CD8 clones derived
from seven biopsies were screened in triplicate cultures for their
responsiveness to staphylococcal enterotoxins SEA, SEB, SED
and SEE (5 ng/ml) in the presence of 5 >< i0 irradiated allogeneic
APCs by measuring 3H-TdR uptake after 60 hours of stimulation.
A mitogenic index (the ratio of mean cpm in stimulated to
unstimulated cultures) greater than 5 was considered positive.
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Table 1. Clinical parameters of recipients and histological findings
Case
nb.°
Immunosuppression
regimen Day of
biopsy'1
.
Histological
diagnosis
Banif
classification
Nadir Peak
Creatinine
CsA
levelInduc/ Maint.°
Grade I/Il acute rejection
1 TT IT d + 36 grade I AIR gi, i2, t2, vO, ahO 180 393 315
7 TI TT d + 28 grade II AIR gi, i2, t3, vO, ahO 132 340 205
8 IT TT d + 19 grade I AIR gi, i3, ti, vO, ahO 150 440 210
11 TI IT d + 25 grade I AIR gO, i3, tO, vO, ahO 120 231 300
13 ALS TT d + 83 grade TI AIR gO, i2, t3, vO, ahO 103 174 188
16 TF TT d + 130 grade I AIR go, ii, t2, vO, ahO 106 139 77
24 ALS TI d + 7 grade I AIR gi, i3, tI, vO, ahl 161 252 267
32 ALS TI d + 26 grade II AIR gi, i2, ti, vi, ahi 161 480 129
33 ALS TT d + 40 grade I AIR gi, i2, t2, ahl 166 205 158
34 TI TT d + 6 grade I AIR gO, i2, ti, ahO 343 658 143
Borderline
2 ALS TI d + 67 BLR go, ii, ti, vO, ahO 155 247 216
3 TF TI d + 16 BLR gi, ii, ti, a2, ahO 282 — 149
4 TT TI' d + 48 BLR gO, ii, ti, vO, ahO 128 390 255
5 TI CsA + Aza d + 23 BLR gO, ii, ti, vO, ahO 138 246 155
15 TI TT d + 9 BLR gO, ii, ti, vO, ahO DGF 163
28 IT
-
CsA + Cs d + 27 BLR
-
gO, i2, ti, vO, DGF 187
"All patients first received a kidney transplantation, except patients #11 and #3, who first received a combined pancreas-kidney transplantation. The
number of HLA mismatches (4.8 1 vs. 3.5 1.5), and the pregraft immunological status (% reactivity against PRA, number of blood transfusion)
were not statistically different between AIR and BLR groups, respectively. Three additional patients (#20, #26 and 30) with a typical CsA toxicity were
also included in the study; all of them received a TI at the time of biopsy.
h Induction treatment [TI, triple therapy (cyclosporine A, corticosteroids, azathioprine); ALS, anti-lymphocyte serumi
Maintenance treatment (TI, triple therapy; CsA, cyclosporine A; Aza, azathioprine; Cs, corticosteroids)
'1dO = day of transplantation
Preparation of EBV-transformed donor B-cell lines and screening
assay for alloreactivily in clones of graft-infiltrating T-cells
Lymph node cells from the donors of kidney allografts to
patients #3 and #16 were incubated for two hours at 37°C with
EBV-containing culture supernatant from the B95-8 marmoset
cell line. Cells were then cultured in the presence of 1 jsg/ml
cyclosporine A for three weeks before being expanded in long-
term culture.
In order to assess alloreactivity, T-cell blasts (5 x 10) from all
CD4 and CD8 clones derived from patients #3 and #16 were
extensively washed, cocultured for 60 hours with 5 X iO irradi-
ated EBV B-cell lines derived from either the related or the
unrelated donor, and 3H-TdR uptake was measured. A mitogenic
index greater than 5 was considered positive.
Characterization of the cytokine profile of T-cell clones
To induce cytokine production in T-cell clones, 10" T-cell blasts
were stimulated for 36 hours with P1-IA (1% vol/vol) in I ml
complete medium, as detailed elsewhere [31]. In order to assess
antigen-induced cytokine production, T-cell blasts (5 X 10) from
alloreactive CD4 and CD8 clones derived from the two pa-
tients (#3 and #16) were each cocultured for 48 hours in 0.5 ml
with 5 X iO irradiated EBV B-cells derived from either of the two
donors, related or unrelated. Culture supernatants were assayed
for IFN-y, IL-4, and IL-S content. Quantitative determinations of
IFN-y or IL-4 were performed using commercial assays (Bio-
Source International Inc., Camarillo, CA, or Quantikine, R & D
Systems, Minneapolis, MN, USA, respectively). For the measure-
ment of IL-5, the murine LyH7.B13 cell line was used as a source
of indicator cells, as detailed elsewhere [31]. Supernatants show-
ing IFN-y, IL-4 or IL-S levels 5 SD over the mean level in control
supernatants derived from irradiated feeder cells alone were
regarded as positive. T-cell clones able to produce IFN-'y, but not
IL-4 or IL-5, were categorized as Thi; clones able to produce IL-4
and/or IL-5, but not IFN-y, were categorized as Th2, and clones
producing both IFN-y and IL-4 or IL-5 were categorized as ThO.
Preparation of mRNA, eDNA and polymerase chain reaction
In 36 randomly selected T-cell clones apparently unable to
produce IFN-y, IL-4 or IL-5, ('null' clones) cytokine mRNA
expression was assessed by 18 hours of stimulation with PMA (10
ng/ml) plus anti-CD3 mAb (200 ng/ml). Messenger RNA(mRNA) was extracted using an mRNA direct isolation kit
(Qiagen Gmbh, Hilden, Germany). The concentration and quality
of mRNA samples were estimated by determining absorbance at
260/280 nm and in all subsequent procedures all samples and all
reactions were handled and performed under identical circum-
stances by the use of master mixes. T-cell clones with definite Thi,
ThO and Th2 cytokine profiles stimulated with PMA plus anti-
CD3 antibody provided positive control mRNA. Using the same
amount of mRNA (50 ng), eDNA was synthesized with M-
MuLV-RT (New England Biolabs, Beverly, MA, USA) and
oligo-dT primers according to the enzyme suppliers' protocol.
eDNA-mix of all samples was amplified under equal conditions by
a 30 cycle PCR using IL-2, IFN-y, IL-4, and IL-S Stratagene (La
Jolla, CA, USA) primers according to the manufacturer's instruc-
tions. Post-PCR samples were analyzed on a 2% Metaphor
agarose gel (FMC, Rockland, ME, USA), stained with ethidium
bromide and photographed under ultraviolet light. 13-actin was
assayed in all specimens to verify the efficiency of eDNA synthesis
from the extracted RNA.
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Table 2. Phenotype of T-cell clones derived from kidney graft biopsies
and efficiency of the cloning procedure
Phenotype and number
of T-cell clones
obtainedaCase number
and diagnosis CD4 CD8
Clonal
efficiency
Acute interstitial rejection (grade I-TI)
1. 26 (38) 42 (62) 91%
7. 31 (48) 33 (52) 83%
8. 29 (55) 24 (45) 71%
11. 32 (76) 10 (24) 53%
13. 41 (77) 12 (23) 70%
16. 14 (64) 8 (36) 29%
24. 16 (64) 9 (36) 23%
32. 49 (73) 18 (27) 86%
33. 23 (46) 27 (54) 66%
34. 18 (46) 21 (54) 52%
Borderline histology
2. 35 (67) 17 (33) 66%
3. 56 (73) 21(27) 98%
4. 29 (62) 18 (38) 61%
5. 44 (66) 23 (34) 87%
15. 34 (62) 21(38) 68%
28. 32 (67) 16 (33) 61%
CsA toxicity
20. 31 (55) 25 (45) 66%
28. 15 (52) 14 (48) 30%
30. 29 (62) 18 (38) 63%
a Percent values are in parenthesis
Results
Phenotype and diversity of the clonal progeny of graft-infiltrating
T-cells
Core biopsy specimens of the kidney graft were obtained in 10
patients with grade I or II AIR and 6 patients with a histology of
BLR (Table 1). Tissue fragments were cultured for nine days in
IL-2-conditioned medium in order to preferentially expand T-
cells activated in vivo. Biopsy specimens were then disrupted and
T-cell blasts were cloned under limiting dilution in the presence of
irradiated allogeneic feeder cells, PHA and IL-2, according to a
highly efficient cloning technique that allows the clonal expansion
of virtually every single T-cell [32]. A total of 829 T-cell clones
were derived from these 16 kidney graft biopsies included in this
study. As shown in Table 2, in the series of 483 T-cell clones
obtained from the 10 patients with AIR, 279 were
CD3CD4CD8 (mean % SD = 58 14) and 204 were
CD3 *CD4_CD8± (42 14). In the series of 346 T-cell clones
obtained from the 6 patients with BLR, the CD4 and CD8
phenotype distribution was similar, 230 T-cell clones being
CD3CD4CD8 (66 4) and 116 CD3CD4CD8 (34 4).
CD4/CD8 ratios in acute and borderline rejection, therefore,
showed no significant difference (1.72 1.01 vs. 1.94 0.39,
respectively), nor did ratios in acute rejection differ substantially
between grade I and grade 11 (1.49 0.95 vs. 2.32 1.25,
respectively). On the 132 clones derived from the two CsA toxicity
biopsies, 56 9% were CD4 and 44 5 CD8. No attempt was
made to study cell yield before cloning, since the size of biopsy
specimens was variable. Finally, no clones could be derived from
a "normal" kidney graft biopsy (Methods).
In general, the frequency of proliferating clones (cloning effi-
ciency), as determined according to the minimum method
reported by Taswell [33], was sufficiently high (range 23 to 98%;
Table 3. Different patterns of proliferative response to staphylococcal
enterotoxins by T-cell clones derived from a kidney graft biopsy
Patient #24 (AIR) T-cell
clones and cytokine
patterns
Degree of responsiveness to:
SEA SEB SED SEE
CD4 Thi
24/3 + — +++ +
24/4 +++ +++ — —
24/5 — — ++ —
24/9 + ++ + +
24/10 +++ ++ — +
24/11 — + ++
24/14 +++ +++ — +++
24/15 +++ — —
24/16 ++ — ++ +
24/19 — — + ++
24/21 + + ++
24/23 — +++ —
24/25 — — +++ ++
CD4 ThO
24/6 +++ — +++
24/8 — +++ +++ —
24/13 + + — +++
CD8 Thi
24/1 — +++ +
24/2 — — — —
24/7 +++ — — +++
24/12 ++ +++ — —
24/17 +++ — — —
24/18 + ++ ++ —
24/20 — + ++ —
24/24 — — ++ —
CD8 ThO
24/22 ++ — — ++
T-cell blasts from each clone (5 X 10) were co-cultured for 60 hours
with irradiated allogeneic PBMC (5 >< 10) in the absence or presence of
staphylococcal enterotoxins A, B, D and E (5 ng/ml). A mitogenic index
lower than 5 is indicated as —, from 5 to 20 as +, from 20 to 100 as ++,
and higher than 100 as +++.
Table 2), and no substantial difference in cloning efficiency was
found between AIR, BLR cases and CsA toxicity (62 23%, 73
15% and 53 20%, respectively).
A reasonable question to be answered was whether the large
series of T-cell clones obtained were polyclonal or merely re-
flected the IL-2-induced selective expansion of a few graft-
infiltrating T-cells. To test this possibility, T-cell clones were
assessed for their proliferative response to superantigens, such as
staphylococcal enterotoxins A, B, D and E, in the presence of
allogeneic APCs. As shown in Table 3, in which the results for a
representative series of clones (patient #24) are set out, the great
majority of T-cell clones showed individual patterns of response to
the four superantigens, indicating that they had expressed differ-
ent T-cell receptor (TCR) V rearrangements. On the basis of
these data we concluded that the cohort of 961 T-cell clones
obtained was adequately representative of the graft infiltrating
T-cells present in each biopsy.
Cytokine profiles of the clonal progeny of graft-infiltrating T-cells
To characterize their cytokine secretion profile, all clones were
stimulated for 36 hours with PHA, and cytokine (IFN-y, IL-4 and
IL-5) secretion was assessed in the culture supernatant. As
expected, no detectable cytokine production was found in any
unstimulated T-cell clones, irrespective of their origin. In contrast,
1880 D'Elios et al: Thi effectors in human kidney graft rejection
Table 4. Percent distribution of cytokine secretion patterns in
PHA-stimulated T-cell clones derived from kidney grafts
Source of T-cell
clones N
Cytokine secretion profilea
Thi ThO Th2 Null"
Grade I/Il acute rejection
CD4+ clones 279 70 14 27 13 2 3 1 3
CD8+ clones 204 90 8 6 6 0 4 4
All clones 483 80 15 17 15 1 2 3 4
Borderline rejection
CD4 clones 230 54 7 27 12 4 7 15 8
CD8 clones 116 55 17 19 9 0 26 23
All clones 346 55 13C 23 11" 2 5" 20 17C
CsA toxicity
CD4 clones 75 52 8 32 6 3 2 13 4
CD8 clones 57 63 11 26 4 0 11 8
All clones 132 57 10 30 6 1 1 12 6
Data are mean SD.
a T-cell blasts from each clone (10"/ml) were stimulated for 36 hours
with PHA (1% vol/vol) and culture supernatants were assayed for their
IFN-y, IL-4 or IL-S content by appropriate assays, as reported in the
Methods section.
No secretion of IFN-y, IL-4 or IL-5.
P < 0.0001 vs. grade I/TI acute rejection, NS vs. CsA toxicity
"P = NS vs. grade I/TI acute rejection or vs. CsA toxicity
upon mitogen stimulation the majority of both CD4 and CD8
T-cell clones derived from AIR biopsies exhibited a cytokine
secretion profile consistent with the Thl pattern (Table 4).
Indeed, 70 and 90% of CD4 and CD8+ AIR clones respectively
produced IFN-y, without detectable IL-4 or IL-S secretion. In the
same series of clones, only 2% of the CD4 and none of the
CD8 T-cell clones expressed the Th2 profile (production of IL-4
and/or IL-5 without detectable IFN-y secretion), whereas 27% of
CD4 and 6% of CD8 clones showed combined production of
Thi-type and Th2-type cytokines (ThO pattern). In spite of their
good viability, a small number of T-cell clones (1% of CD4 and
4% of CD8) were categorized as 'null' clones since no measur-
able IFN-y, IL-4 or IL-S production could be detected in their
supernatants. Taken as a whole, of the 483 T-cell clones derived
from grade I/IT AIR, 80% were ThI, 17% were ThO and only 1%
Th2, suggesting that graft infiltration in AIR is dominated by
Thi-type effector T-cells (Table 4). The Thi pattern was also
predominant in the series of 346 clones derived from cases of
BLR. However, proportions of CD4 and CD8 T-cell clones
expressing the Thi profile were significantly lower (54 and 55%,
respectively; P < 0.0001) than in the series of AIR clones.
Interestingly, this difference was not due to a high proportion of
Th2 (2%) or ThO (23%) clones, but rather to high proportions of
both CD4 (15%) and CD8 (26%) 'null' clones unable to
secrete IFN-y, IL-4 or IL-5. Despite the variability in the propor-
tion of 'null' clones between different BLR patients (range 0 to
30%), 'null' clones overall accounted for 20% of clones, as
compared to 3% in AIR (P < 0.0001). The cytokine secretion
profile of clones (N = 132) derived from the three CsA toxicity
biopsies was not significantly different from the BLR group (Thi
57%, ThO 30%, Th2 1%, Null 12%). The failure of 'null' clones to
secrete detectable amounts of IFN-y, IL-4 or IL-S in response to
PHA was confirmed by assessing the expression of cytokine
mRNA in response to PMA plus anti-CD3 antibody in 36
randomly selected 'null' clones from BLR patients. Indeed, none
of these 36 T-cell clones stimulated for 18 hours with PMA plus
Table 5. Proliferative response and IFN-y production induced by
donor-derived EBV-B-cell lines in alloreactive T-cell clones generated
from biopsies obtained from the kidney graft recipients
Recipient graft-
derived T-ceil
clones (phenotype)
Proliferation (MI)
induced by
EBV.B16 EBV.B3
TFN-y production
(U/mI) induced by
EBV.B16 EBV.B3
Recipient #16 (AIR)
16/2 (CD4 Thi) 337 <5 61 <3
16/7 (CD4 Thl) 82 <5 49 <3
16/21 (CD4 ThI) 504 <5 68 <3
16/11 (CD8 Thi) 55 <5 42 <3
16/16 (CD8 Thi) 128 <5 51 <3
Recipient #3 (BLR)
3/19 (CD4 Thi) <5 406 <3 23
3/56 (CD4 Thi) <5 93 <3 19
3/9 (CD8 Thi) <5 753 <3 21
3/15 (CD8 Thi) <5 398 <3 17
3/37 (CD8 Thi) <5 29 <3 16
Culture conditions are reported in the Methods section.
anti-CD3 expressed IL-2, IFN-y, IL-4 or IL-S mRNA, as assessed
by RT-PCR amplification, whereas all of them showed a clear
signal for J3-actin (data not shown).
An attempt was made to assess the proportion of anti-donor
alloreactive T-cell clones and their cytokine profile in response to
alloantigen stimulation. This was possible in only one patient with
AIR (#16) and one with BLR (#3) for whom EBV transformed
donor-derived B-cell lines were available. In the series of T-cell
clones from the patient with AIR, 2 out of 8 (25%) CD8 and 3
out of 14 (21%) CD4 clones proliferated in response to the
appropriate donor-derived EBV-B cell line. In the series of clones
from the patient with BLR, alloreactivity was shown by 3 out of 21
(14%) CD8 and 2 out of 56 (4%) CD4 clones (Table 5). On
alloantigen stimulation, all the alloreactive CD8 and CD4
T-cell clones, whether from the patient with AIR or the patient
with BLR, confirmed their Thi profile, as assessed by PHA
stimulation. Interestingly, however, at an equal number of T-cell
blasts in culture, antigen-induced IFN-y production was consid-
erably higher in alloreactive clones from the patient with AIR
than in those from the patient with BLR (Table 5).
The quantitative aspects of mitogen-induced cytokine produc-
tion by all T-cell clones derived from both AIR and BLR were
then carefully examined. In both the AIR and BLR series, CD4
clones usually produced larger quantities of IFN-y (about twice as
much) compared to CD8 clones (Table 6). More importantly,
however, a large majority of both CD4 and CD8 clones from
patients with AIR were able to produce significantly higher
quantities of IFN-y (about 3 times as much) compared to T-cell
clones with same phenotype derived from patients with BLR
(Table 6) or CsA toxicity (mean production by all clones 32 S
U/b" cells), but no futher difference in levels of IFN-y production
was found between T-ceil clones from grade 1 (105 58 U/b"
cells/mi) and grade 11(89 24 U/b" cells/mi) acute rejection.
Interestingly, no significant difference was found in mean produc-
tion by ThO and the rare Th2 clones, whether from patients with
AIR or BLR, of IL-4 (0.929 0.558 vs. 0.848 0.284 ng/10"
cells/mI) or IL-S (2.1 0.7 vs. 2.8 0.6 U/b" cells/mi).
Histological and clinical correlation
Even though assessed in single clones, IFN-y production in vitro
correlated quite closely with the density of the cellular infiltrate
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Source of
T-cell clones N
Cytokine production
IFN-y U/mi IL-4 ng/mi
Grade 1/11 acute
rejection
CD4 clones 279 122 60 ND
CD8 clones 204 63 31 ND
All clones 483 100 50 0.9 0.5
Borderline rejection
CD4 clones 230 44 10" ND
CD8 clones 116 18 4' ND
All clones 346 36 7' 0.8 0.3'
CsA toxicity
CD4 clones 75 39 9 ND
CD8 clones 57 22 6 ND
All clones 132 32 8 0.8 0.2
observed histologically and quantified using the "i" item in the
Banif classification applied to characterize biopsy samples from
kidney grafts [29]. This is clearly shown in Figure 1, where the
degree of mononuclear cell infiltration in vivo (that is, the degree
of "i" in the Banif grading) was plotted against mean levels of
IFN-y production in vitro by the T-cell clones derived from the
same biopsy. Regression analysis showed that the degree of cell
infiltration and the level of IFN-y production in the clones were
significantly linked (r = 0.83, P < 0.01). This correlation between
item "i" and levels of IFN-y production in vitro was observed for
both CD4 (r = 0.78, P < 0.01) and CD8 (r = 0.81, P < 0.01)
T-cell clones. As expected, levels of IL-4 production in T-cell
clones did not correlate with the degree of infiltration, nor with
any other parameter in the Banif classification (data not shown).
It is of note that item "i" in the Banif grading was the only clinical
parameter that correlated with levels of IFN-y production in vitro;
other parameters related to clinical outcome, such as peak
creatinine level or increment from nadir (L. Gaber et al, unpub-
lished observations) showed no correlation.
Discussion
This study provided evidence that a substantial majority of
T-cell clones generated from kidney allografts undergoing grade
1/11 AIR exhibited a polarized Thi pattern of cytokine secretion,
regardless of their CD4 or CD8 phenotype. A minority of clones
showed combined production of Thi and Th2 cytokines (mixed
ThO pattern), while those with a polarized Th2 profile were
extremely rare. When T-cell clones were derived from kidney
allografts undergoing BLR, the major qualitative difference ob-
served was a less homogeneous and polarized distribution of Th
patterns, with lower but still predominant proportions of Thi
clones and higher proportions of clones that remained unclassi-
fied ("null clones"), due to their consistent failure to express at
least one of the four cytokines (IFN-y, IL-2, IL-4 or IL-5)
commonly used to categorize human Th cells [281.
The high efficiency of the cloning procedure makes it reason-
able to suppose that the distribution of Thl/Th2 patterns among
clones is an adequate representation of the actual situation in
0 1 2 3 4
i (Banff)
Fig. 1. The level of IFN-y production by T-celi clones derived from biopsies
correlates with the intensity of graft mononuclear cell infiltration. For each
biospy, the mean IFN-y production (U/lU6 cells) of all T-cell clones after
in vitro stimulation with PHA was plotted against the "i" item of the Banif
classification. r indicates the correlation coefficient as determined by linear
regression analysis (r = 0.83).
graft infiltrates during episodes of grade I/Il or borderline rejec-
tion. Indeed, the clonal efficiency achieved in this study was
substantially higher than that previously obtained in T-cells
cloning from rejected graft tissue using EBV-transformed donor-
cell lines as feeder cells in the absence of exogeneous IL-2 [34, 35].
Our cloning approach has already been successfully used to
characterize the functional profile of T-cells infiltrating the thy-
roid in Hashimoto's thyroiditis [36], the retroorbital tissue in
Graves' ophtalmopathy [37], the bronchial mucosa in allergic
bronchial asthma [30] and the gastric antrum in Helicobacterpylori
infection [38]. One reasonable objection could be that the high
number of T-cell clones merely reflects IL-2-induced selective
expansion of a few T-cells. That, however, is unlikely. Although
direct analysis of Vf3 repertoire using monoclonal antibodies or
molecular biology was not feasible because of contaminating
feeder cells, the different TCR V/3 rearrangements expressed by
the majority of graft-derived T-cell clones were demonstrated by
their almost individual response patterns to the four different
staphylococcal superantigens [39].
In previous studies, all the clones that have been derived from
a graft undergoing definitive rejection by cloning in the presence
of donor-derived feeder cells recognized epitopes presented by
donor MHC molecules [6]. Of the present series of graft-derived
T-cell clones, however, as indicated by data from two patients (#3
with BLR and #16 with AIR), proliferation and cytokine produc-
tion in response to donor-derived EBV B-cell lines occurred in
only a fraction (4 to 21% of CD4 and 14 to 25% of CD8). The
conclusion can therefore be drawn that the strategy of "in situ
culture" with IL-2 and highly efficient cloning using polyclonal
mitogen yielded a quite reliable picture of graft infiltrates, which
was an important prerequisite if the interpretation of Thl/Th2
patterns in the clones was to have any clinical relevance.
There is no doubt that the initial specific immune response is
essential to focus the effector mechanisms on the relevant anti-
gen(s) and to trigger the series of events that subsequently lead to
Table 6. Quantitative analysis of mitogen-induced IFN-y and IL-4
production by T-cell clones derived from kidney grafts
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Data are mean SD. ND is not done.
aP = 0.007 vs. grade I/Il acute rejection, NS vs. CsA toxicity
6 P = 0.004 vs. grade I/IT acute rejection, NS vs. CsA toxicity
"P = 0.008 vs. grade I/Il acute rejection, NS vs. CsA toxicity
d P = 0.75 vs. grade I/Il acute rejection or CsA toxicity
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massive nonspecific recruitment of immune cells within the af-
fected tissue. Thus, non-antigen-specific cells generally represent
the dominant population in inflammatory infiltrates [28, 30, 38,
401, and the main source of cytokines that can in turn cause T-cell
activation by antigen-independent mechanisms [41]. The initial
preferential development of antigen-specific cells into the TM or
Th2 phenotype is believed to depend on the cytokines predomi-
nant at the site of initial antigen presentation, the type of APCs,
the nature of the costimulating molecules involved, and the dose
of stimulating antigen(s) [42]. This initial commitment may be
critical for the subsequent differentiation of cells recruited non-
specifically at the site of inflammation.
The presence of a cellular infiltrate with a predominantly Thi
pattern is the hallmark of acute allograft rejection in rodents,
while in some models of allograft tolerance infiltration is associ-
ated with dramatically inhibited TM -cytokine transcription [10,
201. In humans, an increase in the expression of IFN-y in kidney
allografts has been shown to correlate with episodes of rejection
[13], and earlier observations made by Benvenuto et a! [43]
reported the production of IFN-y, but not IL-4, in a series of
clones derived from two end-stage rejection kidneys. In that study,
however, the clones that were the major source of IFN-y were
CD8 rather than CD4 [43]. By assessing the production of
IFN-y, IL-4 and IL-5 concomitantly in these large series of T-cell
clones derived from a number of patients undergoing episodes of
grade I/TI AIR or BLR, our study provides further evidence that
Thi is the dominant cytokine pattern in kidney graft rejection,
with virtually no clone producing IL-4 or IL-5 in the absence of
IFN-y (Th2 pattern). Although the majority of studies performed
at the mRNA levels were unsuccessful in detecting significant 1L4
mRNA accumulation during rejection experimentally or in clini-
cal situations [3, 15, 19, 20, 24], a single group reported elevated
transcription [141, this discrepancy could be due to the non-
quantitative PCR method used.
It has been suggested that Th2 cells play a role, mediated
principally by IL-4, in the induction or maintenance of allograft
tolerance in adult rodents [reviewed in 44], but this possibility has
not yet been verified in humans. Indeed, kidney allograft biopsies
from "tolerant" recipients (that is, with a graft that remains
unaffected) are difficult to obtain and are usually free of any
leukocyte infiltrate, as in the case included in this study (Meth-
ods). The very low proportion of Th2 clones obtained in this study
raises the question of whether the pattern of clones derived in
vitro, rather than reflecting the in situ pattern and the actual
behavior of graft-infiltrating Th cells in vivo, resulted from in vitro
artifacts due to the cloning procedure. However, by using the
same cloning protocol, allergen-specific ThO and Th2 clones were
easily generated from the bronchial mucosa of grass pollen-
sensitive asthmatic patients challenged with the specific allergen
in vivo [30].
More interestingly, a significant correlation was found between
the semiquantitative estimate of cellular infiltration into the graft
(the Banif grading) with the quantitation of IFN-y production at
clonal level. IFN-y is believed to recruit macrophages into the
graft, cause macrophage activation, enhance CTL activation, and
amplify the ongoing immune response by up-regulating the ex-
pression of both MHC and costimulating molecules (such as B7)
on graft parenchymal cells and APCs [2, 25]. In addition, IFN-y
promotes differentiation to Thi cells, both in vitro [45] and in vivo
[46] and provides T-cells with a priming signal for high IFN-y
production and cytolytic activity [47]. Interestingly, some authors
have reported that IFN-y mRNA accumulation could occur
before the clinically symptomatic rejection crisis [10, 13]. How-
ever, our results show that the clones derived from ongoing AIR
are clearly distinguishable from those obtained from BLR (or
nonrejected kidneys) in terms of IFN-y production. Furthermore,
the IFN-y production from the case #28 (BLR stage that
ultimately resulted in a severe steroid-resistant rejection) was not
associated with high IFN-y production. Rather, our data suggest
that the clones remained committed toward Thi differentiation
during acute rejection.
The link between the degree of IFN-y production and the
intensity of interstitial infiltration in the graft suggests that T-cells
expanded ex vivo still retain some properties, such as a capacity for
growth [4, 35], which can be correlated with a clinical parameter
and contribute to a better understanding of rejection mechanisms.
Moreover, while the CD4/CD8 ratios in patients with AIR and
BLR were similar, both the patterns of cytokine secretion (that is,
Thl/ThO ratios) and the levels of IFN-y produced differed signif-
icantly between episodes of grade I/IT AIR and episodes of BLR,
the higher values being associated with more severe interstitial
infiltration. Interestingly, in cases of grade 1/Il AIR or BLR, the
mean magnitude of IFN-y production could not be correlated
with lower levels of cyclosporine A (data not shown).
Taken together, these data reasonably conclude that acute
kidney graft rejection elicits a powerful inflammatory response
that recruits and activates both allospecific and nonspecific Thi
effector cells, which are primed to high IFN-y production. How-
ever, a number of observations argue against the possibility that
the magnitude of graft infiltration and the severity of its destruc-
tive activity depend only on in situ IFN-y produced. First, no
significant T-cell growth activity has been reported for IFN-y
during allogeneic responses [48, 49]. In addition, a graft infiltra-
tion occurs in the experimental donor blood transfusion-induced
tolerance state despite abolished IFN-y transcription [20, 261.
However, the effect of anti-IFN-y mAb on graft survival is still
controversial. If neither we [501 nor others [51] were able to
inhibit the rejection process with anti-IFN-y in rats, others have
reported a prolongation of skin allograft survival [52]. Therefore,
it is difficult to conclude if, in the human situation, there is a causal
relationship between the local IFN-y production and the magni-
tude of cellular response. We favor the possibility that the
intensity of both graft infiltration in biopsies and IFN-y produc-
tion in the clones results from the process of allorecognition
through TCR-stimulation of committed cells, as also suggested by
the strong production of IFN-y induced in alloreactive clones by
stimulation with donor EBV B-cells. However, as other important
cytokines found to be elevated (mRNA accumulation) by others
during ongoing rejections, such as IL-b [15], or IL-6 [53], were
not studied, the correlation between IFN-y production and the "i"
item of the Banif grading does not necessarily imply an exclusive
role of this cytokine in rejection.
Our results also suggest that the clinically problematic "border-
line" type of rejection, sometimes defined by histological analysis,
does not represent a single homogeneous situation, but corre-
sponds rather to a low-grade rejection episode (average IFN-y
production one third less than in grade I/IT) with some heteroge-
neity in the Thl/ThO/Th2 phenotype pattern, a feature which is
also in keeping with the variety of clinical outcomes from these
episodes.
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Appendix
Abbrevations are: AIR, acute interstitial rejection; APC, antigen-
presenting cell; BLR, borderline rejection; CTL, cytotoxic T-lymphocyte;
DGF, delay graft function; EBV, Epstein Barr virus; IFN-y, interferon-
gamma; IL, interleukin; MHC, major histocompatibility complex; PCR,
polymerase chain reaction; PHA, phytohemagglutinin; PMA, phorbol
12-myristate 13-acetate; SE, staphylococcal entcrotoxin; TCR, T-cell
receptor; Th, T-helper.
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